Drugs / Vasopressin
Vasopressin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VASOSTRICT | — | 2014-04-17 | fda.gov ↗ |
Trials 68 · started per year
today
US approved 2014
1
2
1
3
5
1
2
3
1
1
3
2
4
6
4
4
2
4
11
3
5
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT04463394 | Aug 2020 → Feb 2022 | Fontan-associated liver disease, hypotensive disorder | Stanford University | Completed | No outcome recorded |
| Phase 0 | NCT02993640 | Sep 2016 → Mar 2017 | portal hypertension | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02394054 | Jan 2015 → Jul 2016 | — | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 0 | NCT01680718 | Oct 2012 → Sep 2013 | — | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 0 | NCT00420407 | Feb 2007 → Apr 2009 | — | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded Stop: Enrollment |
| Phase 15 trials | ||||||
| Phase 1 | NCT05738148 | Nov 2023 → Jan 2026 overdue | cardiac arrest | University of Alberta | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04093050 | Oct 2019 → Apr 2021 | — | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 1 | NCT01327027 | Sep 2011 → Dec 2015 | — | Bowdoin College | Completed | No outcome recorded |
| Phase 1 | NCT01093768 | Feb 2010 → Apr 2013 | autism spectrum disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1 | NCT00628550 | Apr 2008 → Oct 2010 | cardiac arrest | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03446456 | Sep 2018 → Sep 2026 overdue | — | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 27 trials · 1 met primary | ||||||
| Phase 2 | NCT07614438 | Aug 2026 overdue | chronic thromboembolic pulmonary hypertension | Fondation Hôpital Saint-Joseph | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06547892 | Apr → Oct 2025 overdue | — | Hospital do Coracao | Recruiting | No outcome recorded |
| Phase 2 | NCT05958342 | Jun 2024 → Mar 2027 expected | hemorrhagic disease | Jason Sperry | Recruiting | No outcome recorded |
| Phase 2 | NCT03191240 | Dec 2017 → Aug 2021 | cardiac arrest | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01370096 | Feb 2012 → Sep 2016 | pulmonary hypertension | University of Alberta | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00481572 | Jan → Dec 2007 | infectious disease with sepsis | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 2 | NCT00411879 | Jun 2006 → Apr 2007 | cardiac arrest | University of Athens | Completed | Met primary |
| Phase 2/37 trials · 2 met primary · 1 missed | ||||||
| Phase 2/3 | NCT03483753 | Jan 2019 → Oct 2023 | — | University of Sao Paulo | Withdrawn | Met primary Stop: Business |
| Phase 2/3 | NCT03640949 | Sep 2018 → Jan 2021 | cardiac arrest | Lars Wiuff Andersen | Completed | Met primary |
| Phase 2/3 | NCT03204786 | Feb 2018 → Mar 2024 | autism | Stanford University | Completed | No outcome recorded |
| Phase 2/3 | NCT03088345 | Mar 2017 → Nov 2018 | congenital heart disease, univentricular heart, vascular insufficiency disorder | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2/3 | NCT02975999 | Dec 2016 → Dec 2019 | univentricular heart | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00995839 | Nov 2008 → Feb 2010 | infectious disease with sepsis | University of Roma La Sapienza | Completed | Missed primary |
| Phase 2/3 | NCT00269685 | Jul 2000 → ? | — | University of Sherbrooke | Completed | No outcome recorded |
| Phase 36 trials · 1 met primary | ||||||
| Phase 3 | NCT07423156 | Mar → Aug 2026 overdue | placenta praevia | Allama Iqbal Medical College | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07052084 | Jan 2026 → Feb 2028 expected | infectious disease with sepsis | Assistance Publique Hopitaux De Marseille | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06344442 | Apr → May 2025 overdue | acute kidney injury | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT06464510 | Nov 2024 → Aug 2027 expected | infectious disease with sepsis | Hospital do Coracao | Recruiting | No outcome recorded |
| Phase 3 | NCT05568160 | Jan 2023 → Mar 2026 overdue | — | Centre Hospitalier Universitaire Dijon | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00729794 | Sep 2008 → Nov 2010 | cardiac arrest | University of Athens | Completed | Met primary |
| Phase 414 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT07633600 | Jun 2026 → Jun 2027 expected | — | Jennifer Cutler | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06709573 | Apr 2025 → May 2027 expected | infectious disease with sepsis | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06419075 | Jul 2024 → Jan 2025 | pelvic organ prolapse | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded |
| Phase 4 | NCT06471231 | May 2024 → May 2026 | impaired renal function disease, infectious disease with sepsis | Azienda Usl di Bologna | Unknown | No outcome recorded |
| Phase 4 | NCT06934798 | Apr 2024 → Jul 2025 overdue | arterial disorder | University of Sao Paulo | Recruiting | No outcome recorded |
| Phase 4 | NCT06290596 | Apr → Oct 2024 | uterine disorder | Al-Azhar University | Unknown | No outcome recorded |
| Phase 4 | NCT06265259 | Dec 2023 → Dec 2025 | — | University of Thessaly | Unknown | No outcome recorded |
| Phase 4 | NCT05886192 | May 2023 → Jan 2025 | infectious disease with sepsis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04935814 | Jun 2021 → Aug 2022 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT04602767 | Oct 2020 → May 2024 | acute kidney injury | Thomas Jefferson University | Unknown | No outcome recorded |
| Phase 4 | NCT03815344 | Apr 2017 → Jun 2019 | leiomyoma | Antonios Likourezos | Completed | No outcome recorded |
| Phase 4 | NCT05439460 | Jan 2012 → Jun 2014 | pulmonary arterial hypertension | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00127907 | May 2004 → Oct 2007 | cardiac arrest | Hospices Civils de Lyon | Completed | Missed primary |
| Phase 4 | NCT00799292 | Jan 2004 → Jan 2005 | — | Ascher-Walsh, Charles, M.D. | Completed | Met primary |
| Phase not applicable23 trials | ||||||
| — | NCT07838493 | Sep → Dec 2026 expected | — | University of Electronic Science and Technology of China | Recruiting | No outcome recorded |
| — | NCT06605300 | Oct 2024 → Jul 2025 | — | University of Electronic Science and Technology of China | Completed | No outcome recorded |
| — | NCT06203847 | Jul 2024 → Jul 2026 overdue | cardiac arrest | National Taiwan University Hospital | Recruiting | No outcome recorded |
| — | NCT06329063 | Mar 2024 → Jun 2025 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT06329037 | Mar 2024 → Jun 2025 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT06234592 | Jan 2024 → Jan 2026 overdue | acute kidney injury, infectious disease with sepsis | King's College Hospital NHS Trust | Recruiting | No outcome recorded |
| — | NCT04890470 | Mar 2021 → Dec 2022 | — | University of Electronic Science and Technology of China | Completed | No outcome recorded |
| — | NCT04493554 | Jul → Nov 2020 | — | University of Electronic Science and Technology of China | Completed | No outcome recorded |
| — | NCT04214145 | Jan 2020 → Sep 2021 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT04170751 | Nov 2019 → Sep 2021 | essential hypertension | Yonsei University | Unknown | No outcome recorded |
| — | NCT04053478 | Jul 2019 → Dec 2026 expected | hypotensive disorder | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting | No outcome recorded |
| — | NCT03725553 | Dec 2018 → Jun 2021 | placenta praevia | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT03590873 | Jul 2018 → Jun 2019 | — | Hangang Sacred Heart Hospital | Unknown | No outcome recorded |
| — | NCT04190004 | Jan → Nov 2018 | schizophrenia | National Institute of Mental Health and Neuro Sciences, India | Completed | No outcome recorded |
| — | NCT04715737 | Dec 2017 → Jan 2021 | — | University of Electronic Science and Technology of China | Completed | No outcome recorded |
| — | NCT02526914 | Oct 2015 → Jul 2017 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT02377492 | Mar 2015 → Mar 2017 | leiomyoma | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| — | NCT02223429 | Aug 2014 → Feb 2016 | — | James K. Rilling, PhD | Completed | No outcome recorded |
| — | NCT01800877 | Apr 2013 → Dec 2014 | hypotensive disorder | Francois Lamontagne | Completed | No outcome recorded |
| — | NCT01296269 | Apr 2011 → May 2012 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT02053675 | May 2008 → Apr 2013 | infectious disease with sepsis | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT01566539 | Apr 2008 → Nov 2016 | — | Emory University | Completed | No outcome recorded |
| — | NCT00886262 | Jul 2007 → Aug 2011 | liver failure | Medical University of South Carolina | Completed | No outcome recorded |
| Comparator or background therapy36 trials | ||||||
| Phase 2 | NCT06302998 Comparator | Jun 2024 → Dec 2025 | infectious disease with sepsis | Mansoura University | Unknown | No outcome recorded |
| Phase 2 | NCT07446933 Comparator | Mar 2024 → Oct 2025 | — | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT01962870 Comparator | Dec 2013 → May 2017 | autism spectrum disorder | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT01611935 Comparator | May 2013 → Sep 2016 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01247090 Comparator | Oct 2010 → Aug 2018 | end stage renal failure, hypertensive disorder | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT00624650 Background | Feb 2008 → Jan 2011 | acute lung injury | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2/3 | NCT03930069 Comparator | May 2016 → Jan 2017 | submucous uterine fibroid | Zagazig University | Completed | No outcome recorded |
| Phase 2/3 | NCT00379522 Comparator | Jul 2010 → Oct 2014 | — | Volker Wenzel | Completed | No outcome recorded |
| Phase 3 | NCT05139849 Comparator | Nov 2021 → Jan 2027 expected | post-cardiac arrest syndrome | Tiohundra AB | Recruiting | No outcome recorded |
| Phase 3 | NCT04501861 Comparator | Nov 2020 → Aug 2023 | heart disorder | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT03636451 Background | Oct 2018 → Dec 2020 | uterine disorder | University of California, San Diego | Completed | No outcome recorded |
| Phase 3 | NCT01861015 Comparator | May 2013 → Mar 2014 | leiomyoma | CHA University | Completed | No outcome recorded |
| Phase 3 | NCT01718613 Comparator | Nov 2012 → Mar 2014 | infectious disease with sepsis | Cancer Institute of the State of São Paulo | Completed | No outcome recorded |
| Phase 3 | NCT01505231 Comparator | Jan 2012 → Feb 2013 | — | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT00358579 Comparator | Mar 2006 → Jan 2009 | cardiac arrest | Singapore General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07102615 Comparator | Oct 2025 → Dec 2026 expected | — | Prisma Health-Upstate | Recruiting | No outcome recorded |
| Phase 4 | NCT06217562 Comparator | Feb 2024 → Jul 2026 overdue | infectious disease with sepsis | Intermountain Health Care, Inc. | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05193370 Comparator | Jan → Nov 2022 | infectious disease with sepsis | University of New Mexico | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT03317197 Comparator | Jan 2018 → Aug 2020 | cardiac arrest | Korea University Guro Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02675868 Comparator | Jan → Jul 2016 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02454348 Comparator | Nov 2015 → Nov 2017 | — | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 4 | NCT02118467 Comparator | May 2014 → Oct 2026 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 4 | NCT01393704 Comparator | Jul 2011 → Apr 2015 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01700478 Background | Feb → Apr 2005 | hemorrhagic disease | University Hospital of the West Indies | Completed | Met primary |
| — | NCT05920707 Comparator | Apr → Sep 2023 | — | University of Electronic Science and Technology of China | Unknown | No outcome recorded |
| — | NCT06125184 Comparator | Nov 2022 → Oct 2024 | acute kidney injury, heart failure | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT05315557 Comparator | Apr 2022 → Mar 2023 | cirrhosis of liver, infectious disease with sepsis | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT04874246 Comparator | May → Dec 2021 | leiomyoma | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT03880045 Comparator | Apr 2019 → Mar 2021 | leiomyoma | Aswan University Hospital | Unknown | No outcome recorded |
| — | NCT04302584 Comparator | Jan 2018 → Jan 2019 | acute kidney injury, infectious disease with sepsis | Ain Shams University | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02742974 Background | Oct 2015 → Nov 2017 | — | CAMC Health System | Terminated | No outcome recorded |
| — | NCT01493102 Comparator | Dec 2011 → Dec 2013 | infectious disease with sepsis | Samsung Medical Center | Terminated | No outcome recorded |
| — | NCT01318278 Comparator | Mar 2011 → Jan 2013 | hypotensive disorder | Baylor College of Medicine | Completed | No outcome recorded |
| — | NCT00795366 Comparator | Sep 2008 → Sep 2014 | traumatic brain injury | University of Miami | Completed | No outcome recorded |
| — | NCT00816751 Background | Dec 2007 → Feb 2008 | — | University of California, San Diego | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-08-11 | Impax Laboratories, LLC | Regulatory Amneal launches 4 new Generic products, including Vasopressin single-dose amneal.com ↗
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for four generics products, including vasopressin injection 1mL (single-dose). |
| 2022-07-19 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Receives FDA Approval for Vasopressin amphastar.com ↗
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial. |
| 2021-12-29 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Receives FDA Tentative Approval for Vasopressin amphastar.com ↗
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has tentatively approved the Company's Abbreviated New Drug Application ("ANDA") for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-08-11 | Impax Laboratories, LLC | Amneal launches 4 new Generic products, including Vasopressin single-dose amneal.com ↗ |
| 2022-07-19 | Amphastar Pharmaceuticals, Inc. | Amphastar Receives FDA Approval for Vasopressin amphastar.com ↗ |
| 2021-12-29 | Amphastar Pharmaceuticals, Inc. | Amphastar Receives FDA Tentative Approval for Vasopressin amphastar.com ↗ |
| 2021-04-21 | PharmaIN | Peptides: Arginine vasopressin: Direct and indirect action on metabolism pharmain.com ↗ |
| 2012-10-01 | PharmaIN | Physiological Reviews: Vasopressin V1a and V1b receptors: From molecules to physiological systems pharmain.com ↗ |
| 2004-05-28 | PharmaIN | Anaesthesia: Vasopressin and terlipressin: pharmacology and its clinical relevance pharmain.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 111 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vasopressin | “Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and...” NCT03815344 ↗95“Mean arterial pressure (MAP) will be increased from 65 mmHg to 85 mmHg with a blind drug (Vasopressin at 0.03 IU/min). If MAP does not increase norepinephrine will be titrated...” NCT06125184 ↗ “Protocol-directed vasopressor administration based on hemodynamic monitoring data. Agents included norepinephrine, phenylephrine, epinephrine, dopamine, and vasopressin.” NCT02742974 ↗ “The investigators will use vasopressin as the primary vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients.” NCT06302998 ↗ “Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension” NCT06344442 ↗ “Using Vasopressin \[20 IU/CPR cycle\] injection until the 5th cycle” NCT03317197 ↗ “Vasostrict® (vasopressin injection, USP)” NCT04093050 ↗ “vasopressin (Pitressin® 20Unints/vial)” NCT06203847 ↗ “vasopressin” NCT06709573 ↗ “vasopressin” NCT01800877 ↗ “Vasopressin” NCT07633600 ↗ |
| Known as | arginine vasopressin | “Adult in-patients with cardiac arrest not responsive to two direct current countershocks (when applicable) or asystole or pulseless electrical activity are randomized to...” NCT00411879 ↗13“The neuropeptides arginine vasopressin and oxytocin play key roles in socioemotional processes such as pair bonding and parental care” PMID 25462898 ↗ Oct 2014 “Arginine vasopressin (AVP) and related peptides have diverse effects on social behaviors in vertebrates” PMID 29018407 ↗ Sep 2017 “The hormone arginine vasopressin (AVP), in particular, may prove a useful adjunct during resuscitation.” NCT01611935 ↗ |
| Known as | argipressin | “Vasopressin is commercially available under the name "argipressin".” NCT04935814 ↗ |
| Known as | AVP | “The present study was designed to determine the effects of continuously infused norepinephrine (NE) plus (1) terlipressin (TP) or (2) arginine vasopressin (AVP) or (3) placebo...” PMID 21929764 ↗ Sep 201113“The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli” NCT06329037 ↗ “Although potential links between oxytocin (OT), vasopressin (AVP), and social cognition are well-grounded theoretically” PMID 37310308 ↗ Oct 2021 “addition of vasopressin (AVP), a drug used as a vasopressor but with cathecholamine independent mechanisms” NCT06125184 ↗ “A single dose of 24 IU arginine vasopressin (AVP) is administered via a lyophilized oromucosal lollipop.” NCT07838493 ↗ “The hormone arginine vasopressin (AVP), in particular, may prove a useful adjunct during resuscitation.” NCT01611935 ↗ “Arginine vasopressin (AVP) and related peptides have diverse effects on social behaviors in vertebrates” PMID 29018407 ↗ Sep 2017 “Vasopressin (AVP) is commonly added to norepinephrine (NE) to reverse shock in patients with sepsis.” PMID 29784057 ↗ May 2018 “Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension” NCT06344442 ↗ “the neuropeptide oxytocin (OXT) and vassopressin (AVP) influence moral decision making” NCT04890470 ↗ “Oxytocin (OT) and vasopressin (AVP) have been shown to improve social cognition” PMID 27053769 ↗ Apr 2016 |
| Known as | D-arginine-D-vasopressin | “Vasopressin (D-arginine-D-vasopressin) is an endogenous hormone synthesized by the hypothalamus” NCT04935814 ↗ |
| Known as | Empressin | “20 IU of vasopressin (Empressin®, Amomed Pharma GmbH)” NCT03640949 ↗ |
| Known as | Pitressin | “Adult in-patients with cardiac arrest not responsive to two direct current countershocks (when applicable) or asystole or pulseless electrical activity are randomized to...” NCT00411879 ↗1“vasopressin (Pitressin® 20Unints/vial)” NCT06203847 ↗ |
| Known as | Vasopressin (Vasostrict) (Par Pharmaceutical, Chestnut Ridge, NY). | “Vasopressin (Vasostrict) (Par Pharmaceutical, Chestnut Ridge, NY).” NCT06419075 ↗ |
| Known as | Vasopressins | “Drug: Vasopressins” NCT03191240 ↗ |
| Known as | Vasostrict | “Vasopressin (USP) Injectable Solution [Vasostrict]” NCT03204786 ↗1“Vasostrict® (vasopressin injection, USP)” NCT04093050 ↗ |
| Action | Activate | “vasopressin receptor agonists terlipressin and vasopressin” NCT00995839 ↗ |
| Modality | Peptide | “The goal of this protocol, broadly stated, is to evaluate the effects of the neuropeptides oxytocin and vasopressin on the neural systems involved in social cognition and...” NCT01093768 ↗ |
| Route | Intravenous | “intravenous adrenaline (1mg) or vasopressin (40 IU) at ED” PMID 22353644 ↗ Feb 2012 |
| Target | AVPR1A | “binds to AVPR1a to promote vasoconstriction” NCT06344442 ↗ |